Association of Lp-PLA 2 activity and LDL size with interleukin-6, an inflammatory cytokine and oxidized LDL, a marker of oxidative stress, in women with metabolic syndrome

Atherosclerosis

Volumn 218, Issue 2, 2011, Pages 499-506

  Chae, Jey Sook ^a   Kim, Oh Yoen ^a   Paik, Jean Kyung ^a   Kang, Ryungwoo ^a   Seo, Woo Ju ^a   Jeong, Tae Sook ^b   Sweeney, Gary ^c,d   Lee, Sang Hyun ^e   Lee, Jong Ho ^a  

^a Yonsei University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Institute Pasteur Korea   (South Korea)

^d YORK UNIVERSITY   (Canada)

^e National Health Insurance Corporation   (South Korea)

Author keywords

Interleukin 6; LDL size; Lp PLA 2 activity; Metabolic syndrome; Oxidized ldl; Women

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MENOPAUSE; METABOLIC SYNDROME X; OXIDATIVE STRESS; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; ANTHROPOMETRY; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; LEUKOCYTES; LIPOPROTEINS, LDL; METABOLIC SYNDROME X; MIDDLE AGED; OXIDATIVE STRESS; PARTICLE SIZE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80053243936     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.06.036     Document Type: Article

References (29)

1. 2 in atherosclerosis-biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005, 25:923-931.
2. 2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999, 338:479-487.
3. 2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn 2007, 7:511-517.
4. Tsimihodimos V., Karabina S.A., Tambaki A.P., et al. Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res 2002, 43:256-263.
5. Rizzo M., Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. Q J Med 2006, 99:1-14.
6. Rizzo M., Pernice V., Frasheri A., et al. Small, dense low-density lipoprotein (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. Clin Endocrinol 2009, 70:857-870.
7. 2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005, 51:2264-2273.
8. 2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008, 51:1632-1641.
9. Koh K.K., Han S.H., Quon M.J. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 2005, 46:1978-1985.
10. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
11. 2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 2007, 27:1411-1416.
12. 2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004, 109:837-842.
13. De Keyzer D., Karabina S.A., Wei W., et al. Increased PAFAH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol 2009, 29:2041-2046.
14. 2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways. Cardiovasc Res 2010, 85:845-852.
15. 2 with macrophages and Chlamydia pneumoniae infection among patients at risk for stroke. PLoS One 2010, 5:e11026.
16. 2 in an elderly cohort: the Cardiovascular Health Study. J Am Geriatr Soc 2008, 56:792-799.
17. 2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol 2005, 25:216-221.
18. 2: distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis 2007, 190:388-396.
19. Rachoń D., Myśliwska J., Suchecka-Rachoń K., Wieckiewicz J., Myśliwski A. Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women. J Endocrinol 2002, 172:387-395.
20. 2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study. Am J Clin Nutr 2008, 88:630-637.
21. Gazi I., Tsimihodimos V., Filippatos T., et al. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism 2006, 55:885-891.
22. Wierzbicki A.S. Quality as well as quantity? Beyond low-density lipoprotein-cholesterol-the role of practice size. Int J Clin Pract 2007, 61:1779-1790.
23. 2 in patients with metabolic syndrome and carotid atherosclerosis. Lipids Health Dis 2011, 10:13.
24. Derbent A., Kargili A., Koca C., et al. Serum platelet-activating factor acetylhydrolase activity: relationship with metabolic syndrome in women with history of gestational diabetes mellitus. Gynecol Endocrinol 2011, 27:128-133.
25. Ahonen T., Saltevo J., Laakso M., et al. Gender differences relating to metabolic syndrome and proinflammation in Finnish subjects with elevated blood pressure. Mediators Inflamm 2009, 959281.
26. 2 in leukocyte activation and inflammatory responses. Atherosclerosis 2007, 191:54-62.
27. Papanicolaou D.A., Vgontzas A.N. Interleukin-6: the endocrine cytokine. J Clin Endocrinol Metab 2000, 85:1331-1333.
28. Rader D.J. Inflammatory markers of coronary risk. N Engl J Med 2000, 343:1179-1182.
29. 2 (Lp-PLA2) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults. Lipids Health Dis 2009, 8:19.